Biohaven's 15min Chart Triggers MACD Death Cross, Bollinger Bands Narrowing

According to the 15-minute chart of Biohaven, the MACD indicator has crossed below the signal line, signaling a potential decline in the stock price. Additionally, the Bollinger Bands are narrowing, indicating a decrease in the magnitude of stock price fluctuations. This suggests that the stock price may continue to fall, with a lower likelihood of sudden or drastic price movements.

June 19, 2025 - Biohaven Pharmaceuticals Inc. (BHVN) has seen a significant adjustment in its price target by JP Morgan analyst Tessa Romero. The new target price has been lowered from $68.00 to $55.00, representing a 19.12% decrease [1]. Despite this reduction, Romero maintains an "Overweight" rating, indicating potential upside for the stock.

The adjustment is primarily due to recent developments in Biohaven's pipeline. The U.S. launch of troriluzole for spinocerebellar ataxia has been delayed to the fourth quarter, and potential revenue from BHV-2100 for acute migraine has been excluded following a failed Phase 2 proof-of-concept trial [2].

Analysts remain optimistic about Biohaven's prospects. The average one-year price target from 13 analysts is $54.46, with a high estimate of $75.00 and a low estimate of $21.00, implying an average upside of 274.05% from the current price of $14.56 [1][2]. Additionally, 16 brokerage firms have an average recommendation of 1.6, indicating an "Outperform" status [1][2].

Technical indicators also suggest a potential downward trend. The 15-minute chart of Biohaven shows that the MACD indicator has crossed below the signal line, signaling a potential decline in stock price. The narrowing of the Bollinger Bands indicates a decrease in the magnitude of stock price fluctuations, further suggesting a lower likelihood of sudden or drastic price movements.

References:
[1] https://www.gurufocus.com/news/2933839/biohaven-bhvn-target-price-lowered-by-jp-morgan-analyst-bhvn-stock-news
[2] https://www.gurufocus.com/news/2933341/biohaven-bhvn-price-target-lowered-by-jpmorgan-to-55-bhvn-stock-news